These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11733359)

  • 1. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.
    Saramäki O; Willi N; Bratt O; Gasser TC; Koivisto P; Nupponen NN; Bubendorf L; Visakorpi T
    Am J Pathol; 2001 Dec; 159(6):2089-94. PubMed ID: 11733359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the amplification of EIF3S3 in breast and prostate cancer.
    Nupponen NN; Isola J; Visakorpi T
    Genes Chromosomes Cancer; 2000 Jun; 28(2):203-10. PubMed ID: 10825005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
    Savinainen KJ; Linja MJ; Saramäki OR; Tammela TL; Chang GT; Brinkmann AO; Visakorpi T
    Br J Cancer; 2004 Mar; 90(5):1041-6. PubMed ID: 14997205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.
    Nupponen NN; Porkka K; Kakkola L; Tanner M; Persson K; Borg A; Isola J; Visakorpi T
    Am J Pathol; 1999 Jun; 154(6):1777-83. PubMed ID: 10362802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.
    Okamoto H; Yasui K; Zhao C; Arii S; Inazawa J
    Hepatology; 2003 Nov; 38(5):1242-9. PubMed ID: 14578863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB; Qian J; Lieber MM; Bostwick DG
    Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
    Van Den Berg C; Guan XY; Von Hoff D; Jenkins R; Bittner ; Griffin C; Kallioniemi O; Visakorpi ; McGill ; Herath J
    Clin Cancer Res; 1995 Jan; 1(1):11-8. PubMed ID: 9815882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
    Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
    Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
    El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
    Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
    Schlomm T; Kirstein P; Iwers L; Daniel B; Steuber T; Walz J; Chun FH; Haese A; Kollermann J; Graefen M; Huland H; Sauter G; Simon R; Erbersdobler A
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6579-84. PubMed ID: 18006757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
    Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
    J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
    Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
    Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
    Mark HF; Samy M; Santoro K; Mark S; Feldman D
    Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.